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INTRODUCTIONUpdates in venous disease
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BVenousdisease is highlyprevalent and is a significant causeof
morbidity and mortality in industrialized societies. In fact, acute
and chronic venous disease is much more prevalent than arterial
disease. The prevalence of deep venous thrombosis (DVT) is
roughly 80 per 100,000 persons in the United States annually,
although this is most likely a significant underestimation. It has
been estimated that from 250,000 to 600,000 hospitalizations
occur each year in theUnited States due toDVT. Further, it has
been estimated that one in 20 individuals will develop a DVT in
his or her lifetime. Prospective studies have demonstrated that
DVTdevelops in 10%-13%of bedridden patients in the hospital,
and 29%-33% of intensive care unit patients. In addition, the
incidence ofDVT increases dramatically with advancing age; the
incidence is four-foldhigheramongelderly individuals. In lightof
the rapid growth of the elderly segment of our population, the
incidence of DVT and its complications can be expected to
rapidly grow in the years ahead.
Pulmonaryembolism(PE), themost seriouscomplicationof
DVT, affects 1 per 1000 persons annually in the United States.
However, the reported incidence of PE is felt to substantially
underestimate its true incidence. PE is currently the third leading
cause of death among hospitalized individuals in the United
States and is responsible for at least 650,000 deaths per year.
Autopsy studies have demonstrated that as many as 60% of
individuals who died in the hospital had experienced PEs, and
50% of individuals with pulmonary emboli were not diagnosed
antemortem.With the availability of highly effective inferior vena
cava filters, including temporary retrievable options, the compre-
hensive vascular surgical specialist must play a central role in
identifying the patient at risk and intervening to prevent PEs and
save lives.
While pulmonary embolism represents the most important,
life-threatening complication of acute DVT, chronic venous in-
sufficiency (CVI) or the postphlebitic syndrome is the most
common complication. It is estimated that at least 50% of indi-
viduals will develop CVI after one episode of DVT. It appears
that the manifestations of the postphlebitic syndrome become
apparent as soon as within 1-2 years after the DVT, and the
incidence of this morbid condition increases progressively with
time. In one study of individuals followed for a mean of 39
months after an episode of DVT, 67% reported pain and/or
edemaof the affected limb, 23%developed skin changes, and 5%
had developed at least one skin ulcer. It has been reported that
venous stasis ulcers comprise 90% of lower extremity ulcers.
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orbidity and health care expenditures in this country. In addi-
ion to the deleterious effect ofCVI on the individual’s quality of
ife, it has been estimated that the health care costs of this condi-
ion exceed $1 billion annually in the United States.
The etiology of CVI includes incomplete resolution of the
enous thrombosis and deep venous valvular dysfunction related
o the thrombotic process. Recent studies have demonstrated
hat aggressive treatment of acute DVT with catheter-directed
hrombolysis can rapidly resolve the thrombotic process and
hereby restore venous flow and preserve valve function, and
revent the development of CVI. Vascular surgeons have been
eaders in the field of venous thrombolysis andmust continue to
dvanceaggressive treatment strategies in thispatientpopulation.
While not as morbid as chronic deep venous insufficiency,
aricose veins represent themost commoncirculatorydisorder in
ndustrialized societies. It is estimated that varicose veins affect
oughly half the adult population, with varying degrees of sever-
ty, including from 50% to 55% of women and 40% to 55% of
en.Thedevelopmentofminimally invasive treatment strategies
as provided the option of effective treatment of significant
aricosities unresponsive to conservative measures without the
otential morbidity of traditional open surgery. Vascular sur-
eons have helped pioneer the development and refinement of
his technology and are leaders in the field.
And finally, in the current era of comparative effectiveness
nd necessary pressure for health care cost containment, and in
ight of growing prevalence and the rapidly expanding therapeu-
ic options for venous disease, there is a critical need for informed
eadership in the diagnosis and selection of themost appropriate
nd cost-effective treatment strategies for venous disease and a
omprehensive knowledge base among practitioners.
As editors of the Journal of Vascular Surgery®, we aim to
ighlight issues related to the etiology, diagnosis, and manage-
ent of acute and chronic venous disease; this supplement rep-
esents our first attempt at doing so.We have selected outstand-
ng peer-reviewed manuscripts in clinical, basic science, and case
eports submitted to the Journal. Furthermore, we included a
eview article calling for an intersociety consensus guidelines
tatement for venous ulcers. In addition to independently sub-
itted manuscripts, papers based on presentations made at the
nnual meeting of the American Venous Forum were also in-
luded. We hope that the reader finds the contents of this sup-
lement interesting, informative, and helpful in the care of pa-
ients inflicted with venous disease.
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